FluoGuide A/S

Stockholm Stock Exchange FLUO.ST

FluoGuide A/S EBITDA Margin for the year ending December 31, 2023: -10,378.96%

FluoGuide A/S EBITDA Margin is -10,378.96% for the year ending December 31, 2023, a -1,997.96% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

FluoGuide A/S EBITDA Margin for the year ending December 31, 2022 was -494.72%, a -65.99% change year over year.
FluoGuide A/S EBITDA Margin for the year ending December 31, 2021 was -298.04%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Stockholm Stock Exchange: FLUO.ST

FluoGuide A/S

CEO	Mr. Morten Albrechtsen B.B.A., BBA, M.D.
IPO Date	June 17, 2019
Location	Denmark
Headquarters	Ole MaalOees Vej 3
Employees	7
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years